SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
Seidu S, Alabraba V, Davies S, Newland-Jones P, Fernando K, Bain SC, Diggle J, Evans M, James J, Kanumilli N, Milne N, Viljoen A, Wheeler DC, Wilding JPH.
Seidu S, et al. Among authors: milne n.
Diabetes Ther. 2024 Apr 5. doi: 10.1007/s13300-024-01550-5. Online ahead of print.
Diabetes Ther. 2024.
PMID: 38578397
Review.